$Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma$

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma

This retrospective study investigated the clinical efficacy and safety of bortezomib retreatment in patients with relapsed or refractory multiple myeloma (MM). A total of 30 patients who relapsed or progressed after ≥6 months since the last dose of their previous bortezomib therapy were included in...

Full description

Bibliographic Details
Main Authors:	Ahn, Jae-Sook, Jung, Sung-Hoon, Lee, Seung-Shin, Ahn, Seo-Yeon, Yang, Deok-Hwan, Kim, Yeo-Kyeoung, Kim, Hyeoung-Joon, Lee, Je-Jung
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233662/

Similar Items

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
by: Lee, Seung-Shin, et al.
Published: (2016)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Cerchione, Claudio, et al.
Published: (2016)

Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment
by: Jung, Sung-Hoon, et al.
Published: (2015)

Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
by: Ahn, Jae-Sook, et al.
Published: (2013)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
by: Kim, Yeo-Kyeoung, et al.
Published: (2015)

The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma
by: Jung, Sung-Hoon, et al.
Published: (2014)

A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment
by: Bae, Soo-Young, et al.
Published: (2011)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
by: Kumar, S K, et al.
Published: (2015)

Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma
by: Yang, Deok-Hwan, et al.
Published: (2015)

Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea
by: Kim, Hyo Jung, et al.
Published: (2015)

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
by: Hoang, My-Dung, et al.
Published: (2015)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
by: Park, Hyung-Chul, et al.
Published: (2012)

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
by: Jung, Sung-Hoon, et al.
Published: (2016)

Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
by: Jung, Sung-Hoon, et al.
Published: (2012)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
by: Kim, Yeo-Kyeoung, et al.
Published: (2014)

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
by: San-Miguel, Jesus F., et al.
Published: (2016)

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
by: Mu, Song, et al.
Published: (2015)

Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation
by: Lee, Seung-Shin, et al.
Published: (2015)

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
by: Prince, H Miles, et al.
Published: (2007)

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
by: Offidani, M, et al.
Published: (2013)

Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
by: Cerchione, Claudio, et al.
Published: (2016)

Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients
by: Lin, MaoFang, et al.
Published: (2014)

Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)
by: Therasa Kim, et al.
Published: (2018-07-01)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
by: Hashimoto, Shigeo, et al.
Published: (2016)

Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma
by: Salmenniemi, Urpu, et al.
Published: (2012)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
by: Zhao, Junmei, et al.
Published: (2015)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Alegre, Adrian, et al.
Published: (2011)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael, M, et al.
Published: (2010)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk, Niels WCJ, et al.
Published: (2012)

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
by: Yang, Wen-Chi, et al.
Published: (2015)

Cellular immunotherapy using dendritic cells against multiple myeloma
by: Nguyen-Pham, Thanh-Nhan, et al.
Published: (2012)

Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma
by: Park, Hyung Chul, et al.
Published: (2013)

Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
by: Nguyen-Pham, Thanh-Nhan, et al.
Published: (2012)

Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma
by: Ahn, Jae-Sook, et al.
Published: (2011)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
by: Kim, Kihyun, et al.
Published: (2013)

Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients
by: Hong, Seung-Dok, et al.
Published: (2011)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
by: Field-Smith, Antonia, et al.
Published: (2006)

A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
by: Kim, Youngwoon, et al.
Published: (2012)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
by: Chen, Christine, et al.
Published: (2009)

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
by: Jain, Salvia, et al.
Published: (2011)